microfat

微脂肪
  • 文章类型: Journal Article
    目的:在脂肪移植过程中,从体内取出脂肪组织并注射到皮肤下的不同区域。这篇综述文章的目的是研究脂肪移植在再生医学和复兴中的功效和适用性,包括Nanofat,微脂,还有Millifat.
    方法:作为搜索策略和研究选择,我们使用相关关键字搜索PubMed和Medline数据库,直到2023年(例如,Nanofat,微脂和Millifat,再生医学,和复兴)。
    结果:自体脂肪移植没有个体对移植的过敏反应或排斥反应的风险。自体脂肪组织被认为是面部年轻化的理想填充物,被认为是最具生物相容性和非免疫原性的皮肤填充物。脂肪组织移植可能具有半永久性到永久性的作用。根据最近的报道,脂肪组织具有高比例的成熟干细胞。再生脂肪组织及其固有细胞的作用可以描述为一个明显的过程。取决于手术部位,脂肪组织大小的变化可导致不同的结果。根据地形评估,移植脂肪根据解剖位置和大小分配,如Millifat(2-2.5毫米),微脂肪(1毫米),和Nanofat(500μm或更小)。
    结论:脂肪组织的某些特征增加了其有效性,比如增加干细胞,生长因子,细胞因子,和有效修复的化合物,再生,和复兴。
    OBJECTIVE: During fat transplantation, adipose tissue is removed from the body and injected into different areas under the skin. The goal of this review article is to look into the efficacy and applicability of fat transplantation in regenerative medicine and rejuvenation, including Nanofat, Microfat, and Millifat.
    METHODS: As a search strategy and study selection, we searched the PubMed and Medline databases until 2023 using related keywords (e.g., Nanofat, Microfat and Millifat, Regenerative Medicine, and Rejuvenation).
    RESULTS: Autologous fat transplantation has no risk of an allergic reaction or rejection of the transplant by the individual. Autologous adipose tissue is considered an ideal filler for facial rejuvenation and is suggested as the most biocompatible and non-immunogenic skin filler. Adipose tissue transplant may have semi-permanent to permanent effects. According to recent reports, adipose tissues possess a high percentage of mature stem cells. The effect of regenerating adipose tissue and its intrinsic cells can be described as an obvious process. Variations in the sizes of adipose tissues can result in different results depending on the surgical site. Based on topographic assessment, graft fats are assigned depending on the anatomical locations and the size such as Millifat (2-2.5 mm), Microfat (1 mm), and Nanofat (500 μm or less).
    CONCLUSIONS: Some characteristics of fat tissue increase its effectiveness, such as increasing stem cells, growth factors, cytokines, and compounds effective in repair, regeneration, and rejuvenation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:肥厚性瘢痕是伤口愈合后的纤维化疾病,其特征是过度的细胞外基质沉积。自体微脂肪移植证明了其治疗的有效策略,因为它可以改善疤痕的质地并缓解相关症状。本研究旨在探讨微脂肪对增生性瘢痕的抗纤维化作用的潜在机制。
    方法:在本研究中,我们在小鼠模型中将微脂肪注射到移植的肥厚性瘢痕中,并研究了随后的组织学变化和其中mRNA的差异表达。至于体外研究,我们共培养了微脂肪和增生性瘢痕成纤维细胞(HSF),并通过RNA测序分析了与微脂肪共培养的HSF的分子谱变化.此外,确定可能负责抗纤维化功能的微脂肪的关键转录因子(TFs),我们筛选了差异表达的TFs并用慢病毒转染HSF以过度表达或敲除某些差异表达的TFs。此外,进行了比较分泌组分析,以研究共培养的微脂肪分泌的蛋白质;在施用潜在的抗纤维化蛋白后,检查了HSF基因表达的变化。最后,分析了HSF中关键TF与微脂分泌的抗纤维化脂肪因子之间的关系。
    结果:体内移植的增生性瘢痕模型证实了微脂肪的抗纤维化作用,随着α-SMA阳性肌成纤维细胞数量的减少和纤维化相关基因的表达下调。在体外实验中,共培养的微脂肪抑制了HSF的细胞外基质的产生,与正常皮肤成纤维细胞相比,转录因子ETV4主要在HSF中差异表达。ETV4的过表达在mRNA和蛋白质水平上均显着降低了HSF中纤维化相关基因的表达。微脂肪分泌的胎球蛋白A还可以下调HSF中纤维化相关基因的表达,部分通过上调ETV4表达。
    结论:我们的结果表明,转录因子ETV4对于微脂肪对增生性瘢痕的抗纤维化作用至关重要,微脂肪分泌的胎球蛋白A可以通过上调ETV4的表达来抑制HSF的纤维化特性。微脂肪通过胎球蛋白A/ETV4轴对肥厚性瘢痕产生缓解影响。
    Hypertrophic scar is a fibrotic disease following wound healing and is characterized by excessive extracellular matrix deposition. Autologous microfat grafting proves an effective strategy for the treatment thereof as it could improve the texture of scars and relieve relevant symptoms. This study aims to explore the potential mechanisms underlying the anti-fibrotic effect of microfat on hypertrophic scars.
    In this study, we injected microfat into transplanted hypertrophic scars in mouse models and investigated the subsequent histological changes and differential expression of mRNAs therein. As for in vitro studies, we co-cultured microfat and hypertrophic scar fibroblasts (HSFs) and analyzed molecular profile changes in HSFs co-cultured with microfat by RNA sequencing. Moreover, to identify the key transcription factors (TFs) which might be responsible for the anti-fibrotic function of microfat, we screened the differentially expressed TFs and transfected HSFs with lentivirus to overexpress or knockdown certain differentially expressed TFs. Furthermore, comparative secretome analyses were conducted to investigate the proteins secreted by co-cultured microfat; changes in gene expression of HSFs were examined after the administration of the potential anti-fibrotic protein. Finally, the relationship between the key TF in HSFs and the microfat-secreted anti-fibrotic adipokine was analyzed.
    The anti-fibrotic effect of microfat was confirmed by in vivo transplanted hypertrophic scar models, as the number of α-SMA-positive myofibroblasts was decreased and the expression of fibrosis-related genes downregulated. Co-cultured microfat suppressed the extracellular matrix production of HSFs in in vitro experiment, and the transcription factor ETV4 was primarily differentially expressed in HSFs when compared with normal skin fibroblasts. Overexpression of ETV4 significantly decreased the expression of fibrosis-related genes in HSFs at both mRNA and protein levels. Fetuin-A secreted by microfat could also downregulate the expression of fibrosis-related genes in HSFs, partially through upregulating ETV4 expression.
    Our results demonstrated that transcription factor ETV4 is essential for the anti-fibrotic effect of microfat on hypertrophic scars, and that fetuin-A secreted by microfat could suppress the fibrotic characteristic of HSFs through upregulating ETV4 expression. Microfat wields an alleviative influence over hypertrophic scars via fetuin-A/ETV4 axis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    没有注射治疗已被证明是有效的腕关节骨关节炎。当保守措施失败时,它的管理涉及侵入性手术。基于脂肪干细胞(ADSC)的生物疗法的出现为软骨退行性疾病提供了有希望的治疗方法。微脂(MF)和富含血小板的血浆(PRP)混合物,富含生长因子和ADSC可能是治疗腕关节骨性关节炎的微创注射选择。这项不受控制的前瞻性研究的目的是评估4mL自体MF-PRP关节内注射的安全性。在局部麻醉下进行。次要目的是描述随访12个月时的临床和MRI结果。收集的患者数据是:不良反应的发生,视觉模拟量表(VAS),手臂的残疾,肩手评分(DASH)和患者评分腕部评估(PRWE)评分,手腕力量,手腕活动范围和5级满意度量表。没有严重不良事件记录。疼痛有统计学意义的下降,DASH,在每次随访中观察PRWE和力量。我们的初步结果表明,关节内自体MF和PRP注射可能是腕关节骨关节炎的一种新的治疗策略,可在手术干预前抵抗医学对症治疗。
    No injection treatment has been proven to be effective in wrist osteoarthritis. When conservative measures fail, its management involves invasive surgery. Emergence of biotherapies based on adipose derived stem cells (ADSC) offers promising treatments for chondral degenerative diseases. Microfat (MF) and platelets-rich plasma (PRP) mixture, rich in growth factors and ADSC could be a minimally invasive injectable option in the treatment of wrist osteoarthritis. The aim of this uncontrolled prospective study was to evaluate the safety of a 4 mL autologous MF-PRP intra-articular injection, performed under local anesthesia. The secondary purpose was to describe the clinical and MRI results at 12 months of follow-up. Patients\' data collected were: occurrence of adverse effects, Visual analog scale (VAS), Disabilities of the Arm, Shoulder and Hand score (DASH) and Patient-Rated Wrist Evaluation (PRWE) scores, wrist strength, wrist range of motion and 5-level satisfaction scale. No serious adverse event was recorded. A statistically significant decrease in pain, DASH, PRWE and force was observed at each follow-up. Our preliminary results suggest that intra-articular autologous MF and PRP injection may be a new therapeutic strategy for wrist osteoarthritis resistant to medical symptomatic treatment prior to surgical interventions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:严重萎缩性痤疮疤痕(AAS)仍然是AAS治疗的“致命弱点”。微脂肪和切除治疗的组合是严重AAS的潜在解决方案。
    目的:本研究旨在评估微脂联合切除术治疗重度(4级)AAS的疗效和安全性。
    方法:回顾了2016年9月至2020年12月期间接受微脂和切除术联合治疗的4级AAS患者的数据。术后至少3个月进行治疗后评估。AAS的严重程度根据Goodman的定性分类进行分级。使用Antera3D相机测量凹陷的体积。并发症已记录在案。
    结果:共有42名患者接受了一次治疗。在5例(11.9%)患者中观察到良好的反应,在13个(31.0%)中非常好,在22(52.4%)中表现良好,反应不佳的有2人(4.7%)。凹陷的总体积平均减少28.0%。最常见的轻微副作用是轻度肿胀和瘀伤。未观察到重大并发症。
    结论:微脂联合切除术是治疗重度AAS安全有效的方法。该方法将是严重AAS的重要治疗方法。
    BACKGROUND: Severe atrophic acne scars (AAS) remain the \"Achilles\'s heel\" of AAS treatment. The combination of microfat and subcision treatment is a potential solution for severe AAS.
    OBJECTIVE: This study aimed to evaluate the efficacy and safety of combined microfat and subcision treatment for severe (Grade 4) AAS.
    METHODS: Data of patients with Grade 4 AAS who underwent combined microfat and subcision treatment between September 2016 and December 2020 were reviewed. Post-treatment evaluation was performed at least 3 months postoperatively. The severity of AAS was graded based on Goodman\'s qualitative classification. The volume of concavities was measured using an Antera 3D camera. Complications were documented.
    RESULTS: A total of 42 patients received a single treatment session. Excellent response was observed in 5 (11.9%) patients, very good in 13 (31.0%), good in 22 (52.4%), and poor response in 2 (4.7%). The average reduction of the total volume of concavities was 28.0%. The most common minor side effects were mild swelling and bruising. No major complications were observed.
    CONCLUSIONS: Combined microfat and subcision treatment is a safe and effective treatment for severe AAS. The approach will be a significant treatment for severe AAS.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Chronic wounds affect over 400,000 people in the United States alone, with up to 60,000 deaths each year from non-healing ulcerations. Tissue grafting (e.g., autografts, allografts, and xenografts) and synthetic skin substitutes are common treatment methods, but most solutions are limited to symptomatic treatment and do not address the underlying causes of the chronic wound. Use of fat grafts for wound healing applications has demonstrated promise but these grafts suffer from low cell viability and poor retention at the wound site resulting in suboptimal healing of chronic wounds. Herein, we report on an innovative closed-loop fat processing system (MiniTCTM) that can efficiently process lipoaspirates into microfat clusters comprising of highly viable regenerative cell population (i.e., adipose stromal cells, endothelial progenitors) preserved in their native niche. Cryopreservation of MiniTCTM isolated microfat retained cell count and viability. To improve microfat retention and engraftment at the wound site, microfat was mixed with methacrylated collagen (CMA) bioink and 3D printed to generate microfat-laden collagen constructs. Modulating the concentration of microfat in CMA constructs had no effect on print fidelity or stability of the printed constructs. Results from the Alamar blue assay showed that the cells remain viable and metabolically active in microfat-laden collagen constructs for up to 10 days in vitro. Further, quantitative assessment of cell culture medium over time using ELISA revealed a temporal expression of proinflammatory and anti-inflammatory cytokines indicative of wound healing microenvironment progression. Together, these results demonstrate that 3D bioprinting of microfat-laden collagen constructs is a promising approach to generate viable microfat grafts for potential use in treatment of non-healing chronic wounds.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Facial fat transfer has evolved from simple grafting techniques to smaller lobule (microfat) and adipose-derived stem cell (nanofat) injection techniques. These new methods look to overcome the early limitations of facial fat transfer while meeting increased demand and understanding of the role of volume loss in facial aging. The purpose of this article is to review basic principles of microfat and nanofat and demonstrate one technique for their application.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Clinical Trial
    Wrist osteoarthritis (OA) is one of the most common conditions encountered by hand surgeons with limited efficacy of non-surgical treatments. The purpose of this study is to describe the Platelet-Rich Plasma (PRP) mixed-microfat biological characteristics of an experimental Advanced Therapy Medicinal Product (ATMP) needed for clinical trial authorization and describe the clinical results obtained from our first three patients 12 months after treatment (NCT03164122). Biological characterization of microfat, PRP and mixture were analysed in vitro according to validated methods. Patients with stage four OA according to the Kellgren Lawrence classification, with failure to conservative treatment and a persistent daily painful condition >40 mm according to the visual analog scale (VAS) were treated. Microfat-PRP ATMP is a product with high platelet purity, conserved viability of stromal vascular fraction cells, chondrogenic differentiation capacity in vitro and high secretion of IL-1Ra anti-inflammatory cytokine. For patients, the only side effect was pain at the adipose tissue harvesting sites. Potential efficacy was observed with a pain decrease of over 50% (per VAS score) and the achievement of minimal clinically important differences for DASH and PRWE functional scores at one year in all three patients. Microfat-PRP ATMP presented a good safety profile after an injection in wrist OA. Efficacy trials are necessary to assess whether this innovative strategy could delay the necessity to perform non-conservative surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • DOI:
    文章类型: Journal Article
    Autologous fat transfer techniques have experienced tremendous boom in the recent years. Plastic surgeons use these techniques to enhance both the features of the face and of the body. Over the years, controversies concerning fat harvesting, fat processing and fat injection came up. The authors of this review article describe their own experience with fat harvesting, processing and injection and show some of their own results. In addition, they discuss contemporary data from literature regarding the use and complications of fat grafting to the most common areas treated with fat grafting: breast and face.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号